Drug-induced myopathy and neuropathy

Journal of Clinical Neuromuscular Disease

Volumn 5, Issue 2, 2003, Pages 81-92

  Saleh, Firas G ^a   Seidman, Roberta J ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug toxicity; Nerve muscle

Indexed keywords

AMIODARONE; AMPHOTERICIN; ANTIBIOTIC AGENT; CHLOROQUINE; CHLORPROMAZINE; COLCHICINE; CORTICOSTEROID DERIVATIVE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; DIURETIC AGENT; EMETINE; HALOTHANE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LITHIUM; PARALDEHYDE; PENICILLAMINE; PETHIDINE; SUXAMETHONIUM; TRIAMCINOLONE; TRYPTOPHAN; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

ANAMNESIS; BEHCET DISEASE; BLOOD ANALYSIS; CARDIOMYOPATHY; CARNITINE DEFICIENCY; CEREBELLUM DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTROMYOGRAPHY; GOUT; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOREFLEXIA; HYPOTHYROIDISM; IATROGENIC DISEASE; KIDNEY FAILURE; LIVER DYSFUNCTION; MALARIA; MALIGNANT HYPERTHERMIA; METABOLIC DISORDER; MOTOR UNIT POTENTIAL; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE HYPOTONIA; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; MYOFIBROSIS; MYOPATHY; MYOSITIS; NERVE BIOPSY; NEUROPATHY; NEUROTOXICITY; OPHTHALMOPLEGIA; PARESTHESIA; PHYSICAL EXAMINATION; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SENSORIMOTOR NEUROPATHY; SKIN TINGLING; SYMPTOMATOLOGY;

EID: 4644221339     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131402-200312000-00003     Document Type: Review

References (72)

1. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76:234-242.
2. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. 1997;48: 1234-1238.
3. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41:1235-1239.
4. Herzog AG. Proximal myopathy associated with inhaled steroids. JAMA. 1999;281:37.
5. Sitwell LD, Weinshenker BG, Monpetit V, et al. Complete ophthalmoplegia as complication of acute corticosteroid-and pancuronium-associated myopathy. Neurology. 1991;41:921-922.
6. Hanson P, Dive A, Brucher J, et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve. 1997;20:1371-1380.
7. Lancomis D, Smith T, Chad D. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. 1993;16:84-90.
8. Showalter C, Engel A. Acute quadriplegic myopathy: Analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve. 1997;20: 316-322.
9. Zochodne D. Myopathies in the intensive care unit. Can J Neurol Sci. 1998;25:S40-S42.
10. Minetti C, Hirano M, Morreale G, et al. Ubiquitin expression in acute steroid myopathy with loss of myosin thick filaments. Muscle Nerve. 1996;19: 94-96.
11. Garnett WR. Interactions with hydroxyl methylglutaryl coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52:1639-1644.
12. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. J Neurol Sci. 1999; 143:459-460.
13. Landesman KA, Stozek M, Freeman NJ. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Conn Med. 1999;63:455-457.
14. Alvarez J, Rawdanowicz T, Goldstein J. Rhabdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin. J Thorac Cardiovasc Surg. 1998;116:654-655.
15. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol. 1999;22:295-297.
16. Weissgarten J, Zaidenstein R, Fishman S, et al. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs? Perit Dial Int. 1999; 19:180-182.
17. Clouatre Y, Leblanc M, Ouimet D, et al. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant. 1999;14:1047-1048.
18. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy (CLAM). Neurology. 1991;41:1159-1160.
19. De-Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42:333-337.
20. Simpson DM, Slasor P, Dafni U, et al. Analysis of myopathy in a placebo-controlled zidovudine trial. Muscle Nerve. 1997;20:382-385.
21. Peters BS, Winer J, Landon DN, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med. 1993;86:5-15.
22. Semino-Mora MC, Leon-Monzon, Dalakas MC. L-carnitine prevents destructive effect of zidovudine on human muscle mitochondrial and myotubules in culture. Neurology. 1994;44:A132.
23. Kuncl R, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316: 1562-1568.
24. Younger D, Mayer S, Weimer LH, et al. Colchicine-induced myopathy and neuropathy. Neurology. 1991;41:943.
25. Ducloux D, Schuller V, Bresson-Vautrin C, et al. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant. 1997;12: 2389-2392.
26. Roth R, Itabashi H, Louie J, et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J. 1990; 119:1223-1225.
27. Breil M, Chariot P. Muscle disorders associated with cyclosporine treatment. Muscle Nerve. 1999;22: 1631-1636.
28. Fernandez-Sola J, Campistol J, Casademont J, et al. Reversible cyclosporine myopathy. Lancet. 1990; 335:362-363.
29. Rooney P, Balint G, Szebenyi B, et al. Rheumatic syndromes caused by antirheumatic drugs. Baill Clin Rheumatol. 1991;5:139-173.
30. Thyagarajan D, Day BJ, Wodak J, et al. Emetine myopathy in a patient with an eating disorder. Med J Aust. 1993;159:757-760.
31. Dresser LP, Massey EW, Johnson EE, et al. Ipecac myopathy and cardiomyopathy. J Neurol Neurosurg Psychiatry. 1993;56:560-562.
32. Melegh B, Trombitas K. Valproate treatment induces lipid globule accumulation with ultrastructural abnormalities of mitochondria in skeletal muscle. Neuropediatrics. 1997;28:257-261.
33. Neuromuscular Disease Center, Washington University, St. Louis, MO. Available at: http://www.neuro.wustl.edu/neuromuscular/index.html. Accesse March 24, 2003.
34. Biller J, Asconapé J, Kase CS, et al. Iatrogenic neuromuscular disorders. Continuum. 2001;7:61-90.
35. Scarlato G, Comi GP. Metabolic and drug-induced muscle disorders. Curr Opin Neurol. 2002;15:533-538.
36. Argov Z. Drug-induced myopathies. Curr Opin Neurol. 2000;13:541-544.
37. Wald JJ. The effects of toxins on muscle. Neurol Clin. 2000;18:695-718.
38. Bosch PE, Smith BE. Disorders of peripheral nerves. In: Bradley WG, Daroff RB, Fenichel GM, et al., eds. Neurology in Clinical Practice, vol 2, 3rd ed. Woburn: Butterworth-Heinemann; 2000:2045-2130.
39. Erdem S, Kissel JT, Mendell JR. Toxic neuropathies: drugs, metals, and alcohol. In: Mendell JR, Kissel JT, Cornblath DR, eds. Diagnosis and Management of Peripheral Nerve Disorders. New York: Oxford University Press; 2001:297-343.
40. Chaudhry V, Rowinsky E, Sartorius S, et al. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304-311.
41. Graf W, Chance P, Lensch M, et al. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996;77:1356-1362.
42. Mercuri E, Poulton J, Buck J, et al. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch Dis Child. 1999;81: 442-443.
43. Martinez-Arizala A, Sobol S, McCarty G, et al. Amiodarone neuropathy. Neurology. 1983;33:643-645.
44. Fraser A, McQuenn I, Watt A, et al. Peripheral neuropathy during long term high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry. 1985;8: 576-578.
45. Roelofs R, Hrushesky W, Rogin J, et al. peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34:934-938.
46. Misset J-L. Oxaliplatin in practice. Br J Cancer. 1998; 77:4-7.
47. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13:229-236.
48. Riggs J, Ashraf M, Snyder R, et al. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol. 1988;23:92-94.
49. Apfel SC, Arezzo JC, Lipson L, et al. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992;31:76-80.
50. Fischer SJ, Podratz JL, Windebank AJ. Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC12 cells and p75 null mouse dorsal root ganglia. Neurosci Lett. 2001;308:1-4.
51. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves Bax redistribution and cytochrome-c release but no fas receptor signaling. Neurobiol Dis. 2002;9:220-233.
52. Berger AR, Arezzo JC, Schaumburg HH, et al. 2′-3′-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 1993;43:358-362.
53. Symptoms mimicking the clinical presentation of Guillain-Barré syndrome associated with Zerit (stavudine, d4T). Ottawa: Health Canada, 2002. Available at: http://www.hc-sc.ca/hpb-dgps/therapeut/zfiles/english/advisory/ industry/zeritstavudinee.pdf. Accessed May 6, 2003.
54. Gupta AK, Agarwal MP, Avasthi R, et al. Metronidazole-induced neurotoxicity. JAPI. 2003;51:617-618.
55. Yiannikas C, Pollard JD, McLeod JG. Nitrofurantoin neuropathy. Aust N Z J Med. 1981;11:400-405.
56. White WT, Harrison L, Dumas J. Nitrofurantoin unmasking peripheral neuropathy in a type 2 diabetic patient. Arch Intern Med. 1984;144:821.
57. Kinsella LJ, Green R. 'Anesthesia paresthetica': nitrous oxide-induced cobalamin deficiency. Neurology 1995;45:1608-1610.
58. Polomano RC, Mannes AJ, Clark US, et al. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug paclitaxel. Pain. 2001;94: 293-304.
59. Schiller J, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994;12:241-248.
60. Vahdat I., Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7:1192-1197.
61. Dobkin BH. Reversible subacute peripheral neuropathy induced by phenytoin. Arch Neurol. 1977;34: 189-190.
62. Ramirez JA, Mendell JR, Warmolts JR, et al. Phenytoin neuropathy: structural changes in the sural nerve. Ann Neurol. 1986;19:162-167.
63. Albin R, Albers J, Greenberg H, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology. 1987;37:1729-1732.
64. Parry G, Bredesen D. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35:1466-1468.
65. Berger A, Schaumburg H, Schroeder C, et al. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology. 1992;42: 1367-1370.
66. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309:445-448.
67. Albin R, Albers J. Long-term follow-up of pyridoxine-induced acute sensory neuropathy. Neurology. 1990;40:1319.
68. Nakamura Y, Shimizu H, Nishijima C, et al. Delayed functional recovery by vincristine after sciatic nerve crush injury: a mouse model of vincristine neurotoxicity. Neurosci Lett. 2001;304:5-8.
69. Nozaki-Taguchi N, Chaplan SR, Higuera ES, et al. Vincristine-induced allodynia in the rat. Pain. 2001; 93:69-76.
70. Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother. 2000;34:1136-1138.
71. Bakshi N, Maselli R, Gospe S, et al. Fulminant demyelinating neuropathy mimicking cerebral death. Muscle Nerve. 1997;20:1595-1597.
72. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol. 2000;424:563-576.